{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:23:26Z","timestamp":1760783006881},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T00:00:00Z","timestamp":1190419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s00259-007-0582-3","type":"journal-article","created":{"date-parts":[[2007,9,21]],"date-time":"2007-09-21T12:45:49Z","timestamp":1190378749000},"page":"53-64","source":"Crossref","is-referenced-by-count":34,"title":["Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in \u03b1-emitter therapy for disseminated ovarian cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Sebastian","family":"Kn\u00f6r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumito","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reingard","family":"Senekowitsch-Schmidtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Magdolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,22]]},"reference":[{"key":"582_CR1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies \u2013 Results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.","journal-title":"Cancer"},{"key":"582_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"582_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<128::AID-CNCR21>3.0.CO;2-6","volume":"77","author":"G Bolis","year":"1996","unstructured":"Bolis G, Villa A, Guarnerio P, Ferraris C, Gavoni N, Giardina G, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 1996;77:128\u201331.","journal-title":"Cancer"},{"key":"582_CR4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00259-005-1803-2","volume":"32","author":"O Couturier","year":"2005","unstructured":"Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"582_CR5","first-page":"5084","volume":"63","author":"PE Borchardt","year":"2003","unstructured":"Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084\u201390.","journal-title":"Cancer Res"},{"key":"582_CR6","first-page":"3922s","volume":"9","author":"R Huber","year":"2003","unstructured":"Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, et al. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin Cancer Res 2003;9:3922s\u20138s.","journal-title":"Clin Cancer Res"},{"key":"582_CR7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.4161\/cbt.4.12.2251","volume":"4","author":"BJ Allen","year":"2005","unstructured":"Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318\u201324.","journal-title":"Cancer Biol Ther"},{"key":"582_CR8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00259-006-0311-3","volume":"34","author":"HM Buchhorn","year":"2007","unstructured":"Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, et al. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur J Nucl Med Mol Imaging 2007;34:841\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"582_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/108497804323071904","volume":"19","author":"D Milenic","year":"2004","unstructured":"Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, et al. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004;19:135\u201347.","journal-title":"Cancer Biother Radiopharm"},{"key":"582_CR10","first-page":"1342","volume":"47","author":"J Elgqvist","year":"2006","unstructured":"Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342\u201350.","journal-title":"J Nucl Med"},{"key":"582_CR11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","volume":"100","author":"JG Jurcic","year":"2002","unstructured":"Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233\u20139.","journal-title":"Blood"},{"key":"582_CR12","first-page":"289","volume":"48","author":"MR Zalutsky","year":"2004","unstructured":"Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289\u201396.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"582_CR13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/0929867003374516","volume":"7","author":"A Heppeler","year":"2000","unstructured":"Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971\u201394.","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"582_CR14","first-page":"67S","volume":"46","author":"JC Reubi","year":"2005","unstructured":"Reubi JC, M\u00e4cke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46 Suppl 1:67S\u201375S.","journal-title":"J Nucl Med"},{"key":"582_CR15","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"582_CR16","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1158\/1078-0432.CCR-05-2820","volume":"12","author":"S Kneifel","year":"2006","unstructured":"Kneifel S, Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 2006;12:3843\u201350.","journal-title":"Clin Cancer Res"},{"key":"582_CR17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/cbr.2005.20.52","volume":"20","author":"T Nayak","year":"2005","unstructured":"Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm 2005;20:52\u20137.","journal-title":"Cancer Biother Radiopharm"},{"key":"582_CR18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-05-1264","volume":"12","author":"JP Norenberg","year":"2006","unstructured":"Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006;12:897\u2013903.","journal-title":"Clin Cancer Res"},{"key":"582_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1358\/dnp.2001.14.7.858423","volume":"14","author":"S Sperl","year":"2001","unstructured":"Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L. The uPA\/uPA receptor system as a target for tumor therapy. Drug News Perspect 2001;14:401\u201311.","journal-title":"Drug News Perspect"},{"key":"582_CR20","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1158\/1535-7163.MCT-05-0082","volume":"4","author":"JS Rao","year":"2005","unstructured":"Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 2005;4:1399\u2013408.","journal-title":"Mol Cancer Ther"},{"key":"582_CR21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH04-11-0712","volume":"93","author":"B Setyono-Han","year":"2005","unstructured":"Setyono-Han B, St\u00fcrzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005;93:779\u201386.","journal-title":"Thromb Haemost"},{"key":"582_CR22","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/1381612043383962","volume":"10","author":"J R\u00f8mer","year":"2004","unstructured":"R\u00f8mer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359\u201376.","journal-title":"Curr Pharm Des"},{"key":"582_CR23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2174\/1381612033454612","volume":"9","author":"U Reuning","year":"2003","unstructured":"Reuning U, Sperl S, Kopitz C, Kessler H, Kr\u00fcger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA\/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003;9:1529\u201343.","journal-title":"Curr Pharm Des"},{"key":"582_CR24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1535-7163.MCT-06-0264","volume":"6","author":"TK Stutchbury","year":"2007","unstructured":"Stutchbury TK, Al-Ejeh F, Stillfried GE, Croucher DR, Andrews J, Irving D, et al. Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol Cancer Ther 2007;6:203\u201312.","journal-title":"Mol Cancer Ther"},{"key":"582_CR25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10585-005-5788-9","volume":"22","author":"CF Qu","year":"2005","unstructured":"Qu CF, Song EY, Li Y, Rizvi SM, Raja C, Smith R, et al. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005;22:575\u201386.","journal-title":"Clin Exp Metastasis"},{"key":"582_CR26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canlet.2005.03.060","volume":"234","author":"YJ Song","year":"2006","unstructured":"Song YJ, Qu CF, Rizvi SM, Li Y, Robertson G, Raja C, et al. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 2006;234:176\u201383.","journal-title":"Cancer Lett"},{"key":"582_CR27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4161\/cbt.5.4.2478","volume":"5","author":"SMA Rizvi","year":"2006","unstructured":"Rizvi SMA, Li Y, Song EYJ, Qu CF, Raja C, Morgenstern A, et al. Preclinical studies of Bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol Ther 2006;5:386\u201393.","journal-title":"Cancer Biol Ther"},{"key":"582_CR28","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1021\/jm020254q","volume":"45","author":"N Schmiedeberg","year":"2002","unstructured":"Schmiedeberg N, Schmitt M, Rol C, Truffault V, Sukopp M, B\u00fcrgle M, et al. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 2002;45:4984\u201394.","journal-title":"J Med Chem"},{"key":"582_CR29","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1021\/bi010662g","volume":"40","author":"M Ploug","year":"2001","unstructured":"Ploug M, Ostergaard S, G\u00e5rdsvoll H, Kovalski K, Holst-Hansen C, Holm A, et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry-US 2001;40:12157\u201368.","journal-title":"Biochemistry-US"},{"key":"582_CR30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1515\/BC.2001.150","volume":"382","author":"V Magdolen","year":"2001","unstructured":"Magdolen V, B\u00fcrgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, et al. Cyclo(19,31)[d-Cys(19)]-uPA(19-31) is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001;382:1197\u2013205.","journal-title":"Biol Chem"},{"key":"582_CR31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1515\/bchm.1997.378.3-4.231","volume":"378","author":"M B\u00fcrgle","year":"1997","unstructured":"B\u00fcrgle M, Koppitz M, Riemer C, Kessler H, K\u00f6nig B, Weidle UH, et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997;378:231\u20137.","journal-title":"Biol Chem"},{"key":"582_CR32","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1016\/S0040-4039(00)99290-6","volume":"30","author":"K Barlos","year":"1989","unstructured":"Barlos K, Gatos D, Kallitsis J, Papaphotiu G, Sotiriu P, Yao WQ, et al. Synthesis of protected peptide-fragments using substituted triphenylmethyl resins. Tetrahedron Lett 1989;30:3943\u20136.","journal-title":"Tetrahedron Lett"},{"key":"582_CR33","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1021\/jo00795a005","volume":"37","author":"LA Carpino","year":"1972","unstructured":"Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 1972;37:3404\u20139.","journal-title":"J Org Chem"},{"key":"582_CR34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3011.1990.tb00939.x","volume":"35","author":"GB Fields","year":"1990","unstructured":"Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161\u2013214.","journal-title":"Int J Pept Protein Res"},{"key":"582_CR35","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/chem.200204304","volume":"9","author":"G Thumshirn","year":"2003","unstructured":"Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chem-Eur J 2003;9:2717\u201325.","journal-title":"Chem-Eur J"},{"key":"582_CR36","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1021\/ja00182a041","volume":"112","author":"LA Carpino","year":"1990","unstructured":"Carpino LA, Sadat-Aalaee D, Chao HG, DeSelm RH. [(9-Fluorenylmethyl)oxy]carbonyl (FMOC) amino acid fluorides. Convienient new peptide coupling reagents applicable to the FMOC\/tert-butyl strategy for solution and solid-phase syntheses. J Am Chem Soc 1990;112:9651\u20132.","journal-title":"J Am Chem Soc"},{"key":"582_CR37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1139\/v82-146","volume":"60","author":"A Paquet","year":"1981","unstructured":"Paquet A. Introduction of 9-fluorenylmethyloxycarbonyl, trichloroethoxycarbonyl, and benzylcarbonyl amine protecting groups into O-unprotected hydroxamino acids using succinimidyl carbonates. Can J Chem 1981;60:976\u201380.","journal-title":"Can J Chem"},{"key":"582_CR38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.1994.78","volume":"69","author":"VJ M\u00f6bus","year":"1994","unstructured":"M\u00f6bus VJ, Moll R, Gerharz CD, Kieback DG, Weikel W, Hoffmann G, et al. Establishment of new ovarian and colon-carcinoma cell-lines \u2013 Differentiation is only possible by cytokeratin analysis. Br J Cancer 1994;69:422\u20138.","journal-title":"Br J Cancer"},{"key":"582_CR39","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1021\/ac0580114","volume":"77","author":"C Apostolidis","year":"2005","unstructured":"Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77:6288\u201391.","journal-title":"Anal Chem"},{"key":"582_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0969-8051(94)00126-5","volume":"22","author":"TK Nikula","year":"1995","unstructured":"Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22:387\u201390.","journal-title":"Nucl Med Biol"},{"key":"582_CR41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-59349-9_4","volume":"162","author":"V Magdolen","year":"2003","unstructured":"Magdolen V, Kr\u00fcger A, Sato S, Nagel J, Sperl S, Reuning U, et al. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results Cancer Res 2003;162:43\u201363.","journal-title":"Recent Results Cancer Res"},{"key":"582_CR42","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1073\/pnas.82.15.4939","volume":"82","author":"MP Stoppelli","year":"1985","unstructured":"Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen-activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A 1985;82:4939\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"582_CR43","first-page":"1940","volume":"46","author":"HJ Wester","year":"2005","unstructured":"Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med 2005;46:1940\u20135.","journal-title":"J Nucl Med"},{"key":"582_CR44","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","volume":"37","author":"M Mammen","year":"1998","unstructured":"Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2755\u201394.","journal-title":"Angew Chem Int Ed"},{"key":"582_CR45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cbic.200600339","volume":"8","author":"RM Owen","year":"2007","unstructured":"Owen RM, Carlson CB, Xu JW, Mowery P, Fasella E, Kiessling LL. Bifunctional ligands that target cells displaying the alpha(v)beta(3) integrin. Chembiochem 2007;8:68\u201382.","journal-title":"Chembiochem"},{"key":"582_CR46","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X","volume":"5","author":"A Heppeler","year":"1999","unstructured":"Heppeler A, Froidevaux S, M\u00e4cke HR, Jermann E, Behe M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatized somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974\u201381.","journal-title":"Chem Eur J"},{"key":"582_CR47","first-page":"753","volume":"5","author":"C Will","year":"1994","unstructured":"Will C, Wilhelm O, Hohl S, M\u00f6bus V, Weidle U, Kreienberg R, et al. Expression of urokinase-type plasminogen-activator (uPA) and Its receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion capacity. Int J Oncol 1994;5:753\u201361.","journal-title":"Int J Oncol"},{"key":"582_CR48","first-page":"432","volume":"47","author":"E Vegt","year":"2006","unstructured":"Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006;47:432\u20136.","journal-title":"J Nucl Med"},{"key":"582_CR49","first-page":"528","volume":"47","author":"JE Eerd van","year":"2006","unstructured":"van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006;47:528\u201333.","journal-title":"J Nucl Med"},{"key":"582_CR50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrd1413","volume":"3","author":"DE Milenic","year":"2004","unstructured":"Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"582_CR51","first-page":"248","volume":"50","author":"DM Goldenberg","year":"2006","unstructured":"Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 2006;50:248\u201364.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"582_CR52","first-page":"1012","volume":"46","author":"M Behe","year":"2005","unstructured":"Behe M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012\u20135.","journal-title":"J Nucl Med"},{"key":"582_CR53","first-page":"310","volume":"50","author":"S Panigone","year":"2006","unstructured":"Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: A novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging 2006;50:310\u201321.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"582_CR54","first-page":"2025","volume":"47","author":"D Wild","year":"2006","unstructured":"Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025\u201333.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"582_CR55","first-page":"13S","volume":"46","author":"M Jong de","year":"2005","unstructured":"de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S\u20137S.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"582_CR56","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S\u20136S.","journal-title":"J Nucl Med"},{"key":"582_CR57","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00259-004-1653-3","volume":"32","author":"C Seidl","year":"2005","unstructured":"Seidl C, Schr\u00f6ck H, Seidenschwang S, Beck R, Schmid E, Abend M, et al. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging 2005;32:274\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"582_CR58","first-page":"2804","volume":"61","author":"R Senekowitsch-Schmidtke","year":"2001","unstructured":"Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804\u20138.","journal-title":"Cancer Res"},{"key":"582_CR59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1349-7006.2007.00525.x","volume":"98","author":"R Beck","year":"2007","unstructured":"Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci 2007;98:1215\u201322","journal-title":"Cancer Sci"},{"key":"582_CR60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1160\/TH05-01-0054","volume":"93","author":"K Dan\u00f8","year":"2005","unstructured":"Dan\u00f8 K, Behrendt N, H\u00f8yer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676\u201381.","journal-title":"Thromb Haemost"},{"key":"582_CR61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1160\/TH03-12-0798","volume":"91","author":"N Harbeck","year":"2004","unstructured":"Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004;91:450\u20136.","journal-title":"Thromb Haemost"},{"key":"582_CR62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tibtech.2006.10.011","volume":"25","author":"V Pillay","year":"2007","unstructured":"Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25:33\u20139.","journal-title":"Trends Biotechnol"},{"key":"582_CR63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"JC Reubi","year":"2003","unstructured":"Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389\u2013427.","journal-title":"Endocr Rev"},{"key":"582_CR64","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1667\/RR3105","volume":"161","author":"B Lambert","year":"2004","unstructured":"Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, et al. Renal toxicity after radionuclide therapy. Radiat Res 2004;161:607\u201311.","journal-title":"Radiat Res"},{"key":"582_CR65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"582_CR66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","volume":"30","author":"L Bodei","year":"2003","unstructured":"Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor mediated radionuclide therapy with 90Y DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003;30:207\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"582_CR67","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ijrobp.2005.11.036","volume":"64","author":"JS Jaggi","year":"2006","unstructured":"Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006;64:1503\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"582_CR68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2885.2005.00699.x","volume":"28","author":"T Kakizaki","year":"2005","unstructured":"Kakizaki T, Yokoyama Y, Natsuhori M, Yamada N, Hashimoto M, Sato K, et al. Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. J Vet Pharmacol Ther 2005;28:559\u201364.","journal-title":"J Vet Pharmacol Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-007-0582-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0582-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T18:11:17Z","timestamp":1587924677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-007-0582-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,22]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0582-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,22]]}}}